[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). KDIGO CKD-MBD Clinical Practice Guideline].
KDIGO published the first clinical practice guideline on CKD-MBD in 2009. The work group for this guideline consisted of well-known international experts including Masafumi Fukagawa from Japan and truly global in nature. This guideline is based on strict systemic evidence review and explore a new clinical dimension that aims to improve clinical outcome of individual patient but not only improve values of surrogate markers. This guideline is truly the result of international coordinate effort especially by 5 guideline organizations.
Tsukamoto
Yusuke
Y
Division of Nephrology, Shuwa General Hospital/KDIGO.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D002114:Calcinosis / Q000209:etiology; D002117:Calcitriol / Q000627:therapeutic use; D002908:Chronic Disease; D003956:Dialysis; D004164:Diphosphonates / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000628:therapy; D007391:International Cooperation; D007674:Kidney Diseases / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016030:Kidney Transplantation; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000209:etiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D002117:Calcitriol